COMPARISON OF PERSONALIZED AND STANDARD PROPHYLAXIS BASED ON OCTOCOG ALFA IN PEDIATRIC PATIENTS WITH HEMOPHILIA A

Comparison of personalized and standard prophylaxis prevention therapies based on octocog alfa in pediatric patients with hemophilia A. Studies on a general population (adults and children) demonstrate a statistically significant advantage of personalized prevention therapy over standard prophylaxis prevention therapy in terms of annual bleeding rate (ABR) and annual joint bleeding rate (AJBR) while studies on a pediatric population included insufficiently large populations, however, their results demonstrate a numerical advantage of personalized approach over standard prevention strategy prophylaxis regimen.